MarketLens

Is Zai Lab's "Dual-Engine Strategy" Driving Global Growth

3 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Amazon's AI Ambition: Is Alexa+ the Next Growth Engine

5 months ago

Silver's Dual Engine: Why Industrial Demand and Safe-Haven Flows Are Fueling the White Metal's Surge

5 months ago

Is Valmont Industries' Infrastructure Segment a Reliable Growth Engine

5 months ago

Is Rocket Lab's Recent Pullback an Opportunity or a Warning Sign

5 months ago

Zai Lab Q2 Earnings Call Highlights

Zai Lab's Q2 net product revenue rose 11% sequentially to $105.8 million, as the company continues investing in a pipeline aimed at transitioning into a global biopharmaceutical business.

ZLAB

Stock News•1 months ago

Hutchmed: Bullish On Their Commercial Prospects And Pipeline Catalysts

Hutchmed's oncology franchise growth, Fruzaqla international rollout, and improving China execution could boost recurring revenues. Late-stage immunology assets and pipeline options like Sovleplenib a...

HCM

Stock News•2 months ago

China's Original Innovative Drug Cipepofol Approved for Marketing by the U.S. FDA

The U.S. FDA approved Haisco Pharmaceutical's Cipepofol injection for marketing as a Class 1 innovative intravenous anesthetic. This regulatory milestone marks the first time a Chinese-developed innov...

Stock News•2 months ago

This Emerging Risk Is Unlike Anything the Biotech Industry Has Ever Experienced

Biotech firms are increasingly licensing programs from a single geographic region, marking a shift in industry strategy. This concentration of external development creates a new, unprecedented risk pr...

SMMT